Sci Tech Daily A new experimental vaccine takes aim at one of tuberculosis’s most stubborn defenses: the ability of bacteria to persist despite treatment.
In a study published in the Journal of Clinical Investigation, researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health report developing a therapeutic DNA vaccine delivered through the nose for tuberculosis (TB). The vaccine combines two genes designed to train the immune system to target drug-tolerant bacterial “persisters,” which can survive long courses of antibiotics and lead to disease relapse.